^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRLX 93936

    i
    Other names: PRLX 93936, PRLX 82845, erastin analogue
    Associations

    News

    Trials
    Company:
    Prolexys
    Drug class:
    RAS inhibitor, Signal transduction pathway inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Cisplatin synergizes with PRLX93936 to induce ferroptosis in non-small cell lung cancer cells. (PubMed, Biochem Biophys Res Commun)
    In the current study, we showed that cisplatin and PRLX93936, an analog of erastin that has been tested in clinical trials, demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells. Nrf2 silencing increased this sensitivity while inhibition of Keap1 attenuated it. Overall, our data reveal a new effective treatment for NSCLC by synergizing cisplatin and PRLX93936 to induce ferroptosis.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    GPX4 expression
    |
    cisplatin • erastin • PRLX 93936